Elicio Therapeutics, Inc. (ELTX)
CIK 1601485 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 19.1M shares as of May 8, 2026 (10-Q). Share count fell from 30.1M to 8.4M between May 5, 2023 and Aug 10, 2023, a pattern consistent with a reverse split (roughly 1-for-4); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| July Pre Funded Warrants | 1.8M | not tagged | — | — |
| Pre Funded Warrant | 1.6M | $0.01 | 5y | — |
| July Common Warrant One | 1.6M | $5 | — | — |
| January Common Warrants | 1.3M | $7.8 | 5y | — |
| January2025 Common Warrants | 1.3M | $7.8 | — | FV $9.7M |
| March2024 Pre Funded Warrants | 1.0M | $0.01 | — | — |
| July Common Warrants | 441,500 | $5 | 5y | — |
| July Pre Funded Warrants and July Common Warrants | 200,000 | not tagged | — | — |
| Elicio Warrants | 144,814 | $53.59 | — | — |
| June2025 Common Warrants | 103,225 | $7.75 | — | — |
| Angion Warrants | 3,950 | $76 | — | — |
| June2025 Warrants | not tagged | not tagged | — | FV $600,000 |
Tranches exactly as the company dimensioned them in its 10-Q filed May 11, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 6.2M underlying shares, as reported Mar 31, 2026 (10-Q).
Reported exercise price: $4.68 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 25.3M = 19.1M O/S + 6.2M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Senior Secured Convertible Promissory Note | $10.0M | — | not tagged | 3%-12.5% | — |
Notes exactly as the company dimensioned them in its 10-Q filed May 11, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 19.1M | May 8, 2026 |
| + July Pre Funded Warrants (if exercised) | 1.8M | Jul 31, 2024 |
| + Pre Funded Warrant (if exercised) | 1.6M | Mar 31, 2026 |
| + July Common Warrant One (if exercised) | 1.6M | Mar 31, 2026 |
| + January Common Warrants (if exercised) | 1.3M | Jan 31, 2025 |
| + January2025 Common Warrants (if exercised) | 1.3M | Jan 31, 2025 |
| + March2024 Pre Funded Warrants (if exercised) | 1.0M | Mar 31, 2026 |
| + July Common Warrants (if exercised) | 441,500 | Mar 31, 2026 |
| + July Pre Funded Warrants and July Common Warrants (if exercised) | 200,000 | Mar 31, 2026 |
| + Elicio Warrants (if exercised) | 144,814 | Mar 31, 2026 |
| + June2025 Common Warrants (if exercised) | 103,225 | Mar 31, 2026 |
| + Angion Warrants (if exercised) | 3,950 | Mar 31, 2026 |
| Fully diluted estimate | 28.5M | +49.5% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $400.8Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 4 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ELTX workspace